Evidence map›Paper›PMID 25444567›Full record

ArticleInternational journal of medical microbiology : IJMM2014

Random insertion and gene disruption via transposon mutagenesis of Ureaplasma parvum using a mini-transposon plasmid.

Ali F Aboklaish, Emilie Dordet-Frisoni, Christine Citti, Mark A Toleman, John I Glass, O Brad Spiller

Open access · greenAbstract read
In one paragraph

Article in International journal of medical microbiology : IJMM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Improved transformation efficiency inMicrobiology spectrum · 2023
    Article
  3. Review
  4. Article
  5. Serum Resistance ofPathogens (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Article
  8. Large-Scale Analysis of theFrontiers in microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Ali F AboklaishCardiff University, School of Medicine, Department of Child Health, 5th floor University Hospital of Wales, Cardiff CF14 4XN, UK; Sebha University, Faculty of Engineering and Technology, Medical Laboratory Sciences Department, PO Box 68, Libya.
Emilie Dordet-FrisoniINRA, UMR 1225, IHAP, 31076 Toulouse, France; Université de Toulouse, INP, ENVT, UMR1225, IHAP, 31076 Toulouse, France.
Christine CittiINRA, UMR 1225, IHAP, 31076 Toulouse, France; Université de Toulouse, INP, ENVT, UMR1225, IHAP, 31076 Toulouse, France.
Mark A TolemanCardiff University, School of Medicine, Institute of Infection and Immunity, Cardiff CF14 4XN, UK.
John I GlassJ. Craig Venter Institute, Rockville, MD, USA.
O Brad SpillerCardiff University, School of Medicine, Department of Child Health, 5th floor University Hospital of Wales, Cardiff CF14 4XN, UK. Electronic address: SpillerB@cardiff.ac.uk.
Cardiff University · GBInteraction Hôtes Agents Pathogènes · FRJ. Craig Venter Institute · USSebha University · LYUniversité de Toulouse · FR

Funding

Genetic Manipulation of Unreaplasma spp. Infecting Humans using Synthetic GenomicR21AI098057 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI GLASS, JOHN IRVIN · 2012 to 2013
$467k
NIAID NIH HHS R21 AI098057NIAID NIH HHS R21 AI098057-02
6 · The paper itself

Abstract

While transposon mutagenesis has been successfully used for Mycoplasma spp. to disrupt and determine non-essential genes, previous attempts with Ureaplasma spp. have been unsuccessful. Using a polyethylene glycol-transformation enhancing protocol, we were able to transform three separate serovars of Ureaplasma parvum with a Tn4001-based mini-transposon plasmid containing a gentamicin resistance selection marker. Despite the large degree of homology between Ureaplasma parvum and Ureaplasma urealyticum, all attempts to transform the latter in parallel failed, with the exception of a single clinical U. urealyticum isolate. PCR probing and sequencing were used to confirm transposon insertion into the bacterial genome and identify disrupted genes. Transformation of prototype serovar 3 consistently resulted in transfer only of sequence between the mini-transposon inverted repeats, but some strains showed additional sequence transfer. Transposon insertion occurred randomly in the genome resulting in unique disruption of genes UU047, UU390, UU440, UU450, UU520, UU526, UU582 for single clones from a panel of screened clones. An intergenic insertion between genes UU187 and UU188 was also characterised. Two phenotypic alterations were observed in the mutated strains: Disruption of a DEAD-box RNA helicase (UU582) altered growth kinetics, while the U. urealyticum strain lost resistance to serum attack coincident with disruption of gene UUR10_137 and loss of expression of a 41 kDa protein. Transposon mutagenesis was used successfully to insert single copies of a mini-transposon into the genome and disrupt genes leading to phenotypic changes in Ureaplasma parvum strains. This method can now be used to deliver exogenous genes for expression and determine essential genes for Ureaplasma parvum replication in culture and experimental models.

Indexed as

DNA Transposable ElementsGene Knockout TechniquesGenetics, MicrobialMutagenesis, InsertionalPlasmidsTransformation, BacterialUreaplasmaDNA Transposable ElementsGene disruptionRNA helicaseTransposon mutagenesisUreaplasma parvumUreaplasma urealyticum

Identifiers

PMID25444567
PMCPMC4450083
OpenAlexW2092820689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.